Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

OcuMension Approved to Launch Novel Uveitis Therapy in China

publication date: Jun 21, 2022

OcuMension Therapeutics, a Shanghai ophthalmology company, was approved to launch Yutiq® (fluocinolone acetonide intravitreal implant) 0.18mg to treat chronic non-infectious uveitis in the posterior segment of the eye. It is the first of OcuMension’s ophthalmology pipeline to be approved. OcuMension makes the point that Yutiq was tested in a “real world” study – not a clinical trial -- in China’s Boao Lecheng Pilot Zone, which allows administration of drugs that haven’t been approved by China’s NMPA. In 2020, OcuMension acquired China rights to Yutiq from EyePoint Pharma of Boston. More details....

Stock Symbol: (HK: 1477)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital